Ubroseal blue Dry Cow 2.6 g intramammary suspension for cattle

País: Irlanda

Língua: inglês

Origem: HPRA (Health Products Regulatory Authority)

Ingredientes ativos:

Bismuth subnitrate, heavy

Disponível em:

Univet Limited

Código ATC:

QG52X

DCI (Denominação Comum Internacional):

Bismuth subnitrate, heavy

Dosagem:

2.6 g/syringe

Forma farmacêutica:

Intramammary suspension

Tipo de prescrição:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupo terapêutico:

Cattle

Área terapêutica:

VARIOUS PRODUCTS FOR TEATS AND UDDER

Indicações terapêuticas:

Miscellaneous

Status de autorização:

Authorised

Data de autorização:

2018-02-02

Características técnicas

1
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Ubroseal blue Dry Cow 2.6 g intramammary suspension for cattle
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 4 g intramammary syringe contains:
ACTIVE SUBSTANCE:
Bismuth subnitrate, heavy
2.6 g
EXCIPIENTS:
QUALITATIVE
COMPOSITION OF EXCIPIENTS AND
OTHER CONSTITUENTS
QUANTITATIVE
COMPOSITION
IF THAT INFORMATION
IS ESSENTIAL
FOR PROPER ADMINISTRATION OF THE
VETERINARY MEDICINAL PRODUC
t
_ _
Paraffin, liquid
Aluminium Di Tri Stearate
Silica, colloidal anhydrous
Indigo Carmine AL Lake E 132
0.02 g
A blue intramammary suspension
3.
CLINICAL INFORMATION
3.1
TARGET SPECIES
Cattle (dairy cows at drying off).
3.2
INDICATIONS FOR USE FOR EACH TARGET SPECIES
Prevention of new intramammary infections throughout the dry period.
In cows considered likely to be free of sub-clinical mastitis, the
veterinary medicinal product can be
used on its own in dry cow management and mastitis control.
Selection of cows for treatment with the veterinary medicinal product
should be based on veterinary
clinical judgement. Selection criteria may be based on the mastitis
and cell count history of individual
cows, or recognised tests for the detection of sub-clinical mastitis
or bacteriological sampling.
3.3
CONTRAINDICATIONS
Do not use in lactating cows. See section 3.7. Do not use the
veterinary medicinal product alone in
cows with sub-clinical mastitis at drying off. Do not use in cows with
clinical mastitis at drying off.
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
3.4
SPECIAL WARNINGS
None.
3.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for safe use in the target species:
2
It is good practice to observe dry cows regularly for signs of
clinical mastitis. If a sealed quarter
develops clinical mastitis, the affected quarter should be stripped
out manually before appropriate
therapy is instituted. To reduce the risk of contamination, do not
immerse the syringe in water. Use
the syringe only once. It is important to observe strict aseptic
tech